【Exclusive】MagicRNA, Leader in In Vivo CAR-T, Closes Hundreds of Millions Yuan Series B; Platform & Pipeline Earn Sustained Recognition from Top Investors and Global Academia

Recently, Shenzhen Hongxin Biotechnology Co., Ltd. (hereinafter referred to as MagicRNA) announced the completion of its Series B financing round. The round was led by funds under CICC Capital, with Bayland Capital serving as Co-Lead Investor. Follow-on investors include Guokai VC, BOC Financial Asset Investment Co., Ltd., SND Ventures Group and Guoshun Investment, alongside existing shareholders MPC, IDG Capital, Nanling Capital, Huatai Genscript Fund, Sino Biopharmaceutical Limited (China Bio Leading Fund) and Goldport Capital. The total financing amount reached hundreds of millions of RMB. ApexCapital acted as the exclusive financial advisor.

Founded in December 2021, MagicRNA is dedicated to developing advanced immunotherapies based on in vivo LNP-mRNA cell-targeted delivery technology. The company has successfully overcome the industry bottleneck of "extrahepatic non-APC targeted delivery of mRNA" and built a proprietary engineered cell-targeted delivery platform that achieves internationally leading standards in manufacturability and targeted delivery efficiency. Leveraging this platform, MagicRNA's in vivo CAR-T candidate HN2301 completed dosing of the first patient with SLE in Q1 2025, marking the world's first first-in-human clinical trial of cell-targeted LNPs.

To date, dozens of patients with various autoimmune diseases have been enrolled in the HN2301 clinical trial. No hepatotoxicity or Grade >2 CRS has been observed across all dose cohorts, demonstrating sustained and outstanding safety profiles.

In terms of efficacy, preliminary clinical findings from the first cohort of HN2301 patients have been published in the internationally renowned top journal "The New England Journal of Medicine (NEJM)" and were named among the Top 10 Advances at the 2025 American College of Rheumatology (ACR) Annual Meeting. Following continuous iterative optimization, efficacy data from the latest cohort of HN2301 patients have been further improved. Deep depletion of peripheral blood and tissue B cells has been observed, translating into sustained and profound clinical remission, setting a new global benchmark for in vivo CAR-T efficacy in autoimmune diseases. Relevant studies have been selected for oral presentations at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting and featured in the Highlights program of the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress, fully demonstrating high recognition of HN2301 within the global academic community.

Over the past year, the company has efficiently completed three rounds of market-oriented financing, reflecting strong capital market recognition and robust resource attraction capacity for its proprietary Engineered Cell-targeted LNP (EnC-LNP) platform and globally leading in vivo CAR-T asset HN2301. Following the completion of this financing, the company will further consolidate its leading position in the in vivo CAR-T sector and accelerate the China and US IND filings, global clinical development and business collaboration for HN2301.